Teleflex Announces First Patient Enrollment in ACCESS-MANTA Registry - Seite 2

The study chair is George Dangas, MD, PhD, Professor of Medicine (Cardiology), and Surgery, and the Director of Cardiovascular Innovation at the Zena and Michael A. Wiener Cardiovascular Institute at the Icahn School of Medicine at Mount Sinai. The principal investigators of the study include Sahil Khera, MD, Interventional Director of the Structural Heart Program at The Mount Sinai Hospital, and Danny Dvir, MD, Director of Interventional Cardiology at Shaare Zedek Hospital Center, Jersualem.

“We are excited that Mount Sinai Medical Center is spearheading the Teleflex ACCESS-MANTA Registry,” said Dr. Khera, Co-Global Principal Investigator. “The study focuses on on-label use of the MANTA Device, appropriate patient selection using pre-TAVR CT imaging, and proper vascular access, all of which reflect the standard practice at our world class, high-volume TAVR center. We look forward to this contribution to the advancement of large bore access and closure.”

About the MANTA Vascular Closure Device

The MANTA Vascular Closure Device is the first commercially available biomechanical vascular closure device designed specifically for large bore femoral arterial access site closure.⁴ Since the first implantation in 2014, receiving its CE mark in 2016, and FDA approval in 2019, the MANTA Device has been well studied in over 10,000 patients and in 70+ publications. Over 150,000 units have been sold globally.⁴

Available in 14 and 18 Fr. sizes, the MANTA Device is indicated for closure of femoral arterial access sites while reducing time to hemostasis following the use of 10-20 Fr. devices or sheaths (12-25 Fr. O.D.) in endovascular catheterization procedures. The technology creates an alternative to cut down and suture-mediated closure for large bore procedures and has proved useful in TAVI/TAVR, EVAR/PEVAR/TEVAR, and BAV.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.